| abstract |
A transmucosal administration formulation comprising at least an absorption promoter and a compound having a vasodilating action in a bioactive peptide, which can be used in combination with an absorption promoter and a compound having a vasodilating action to increase the absorption of the target bioactive peptide. Therefore, it is very useful as a physiologically active peptide preparation which requires long-term administration since it can self-administer without pain of a patient by injection.n n n Here, the physiologically active peptides include insulin, calcitonin, human PTH, somatostatin, glucagon, and the like, and the absorption promoters include bile salts, cyclodextrins, phospholipids, nonionic surfactants, higher fatty acids, and the like. Examples of the compound having a calcium channel inhibitor include prostaglandin E1, isosorbide nitrate, nitroglycerin and the like. |